San Diego-based Aragon Pharmaceuticals, a developer of treatments for hormonally driven cancers, said today that it has raised $22M in a Series B funding. The funding came from Aisling Capital, OrbiMed Advisors, and the Column Group. As part of the funding, BRett I.W. Zbar, M.D. of Aisling Capital joins the company's board. Aragon said the new funding will be used to advance its ARN-509 candidate into clinical trials. Aragon is initially targeting prostate and breast cancer with its treatments. The new funding brings the company's total raised to $30M. More information »